Rasha Aboelhassan: Clinical research goes beyond answering research questions

Rasha Aboelhassan shared a post on LinkedIn:

“One of the best aspects of clinical research is that when it goes beyond answering research questions:
In Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC).

Analysis did not stop in overall survival for all subgroups. Analysis answers the important question: What happened to those patients who had disease progression on STRIDE protocol ?

They had the worst prognosis and worst overall survival, even after stopping treatment and having new subsequent lines.

this means that the next step is to investigate the causes of failure for those patients who have resistant HCC clones to many lines of treatment.

Lorenza Rimassa : thanks for your fruitful interactive discussion.”

Source: Rasha Aboelhassan/LinkedIn

Rasha Aboelhassan is a Senior Oncology Consultant at Nasser Institute Hospital. In addition to her clinical role, she volunteers as a reviewer for the World Journal of Surgical Oncology, contributing to advancements in the field and is in the Editorial Staff of Egyptian Journal of Human Genetics.